NEW ORLEANS — Elecoglipron, a novel oral GLP-1 receptor agonist (RA), led to significant reductions in A1c and moderate reductions in body weight in people with type 2 diabetes (T2D), according to the results of the phase 2b SOLSTICE trial. In addition, in the phase 2 VISTA trial…
Read More
Novel Oral GLP-1 Shows A1c and Weight-Loss Benefits
